Analysis of:
Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data (pharmalive.com)
Exforge, a combination of 2 widely prescribed antihypertensives will provide give Novartis an extension of its blockbuster Diovan. However it wont save the company
Analysis of:
Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data (pharmalive.com)
Exforge (valsartan/amlodipine) is likely to be well received by physicians who have been fond of Lotrel and prefer branded hypertensive therapies to generic agents.
Analysis of:
Chairman Baucus and Ranking Member Grassley Comment on New England Journal of Medicine Report on Avandia (www.pharmalive.com)
Avandia showed significantly higher risk for MI and CV death in meta-analysis and will likely be pulled from the market. We need CV outcome studies before approval for chronic disease drugs for HTN, DM, and dyslipidemia..
Analysis of:
Ranbaxy Receives Tentative FDA Approval For Fexofenadine Hydrochloride Tablets (www.medicalnewstoday.com)
This is the second generic version of Fenofexadine(Allegra). Its presence on the market should result in lower prices for this generic drug. It puts even greater pressure on Zyrtec and Clarinex to maintain market share.
Analysis of:
Remote Patient Monitoring and Disease Management Solutions Key to Promoting Growth in U.S. Tele-Health Solutions Market (sev.prnewswire.com)
Remote monitoring is one of the most important areas of development in the field of cardiac arrhythmias and will play an important role in the field of tele-medicine. The applies to the cardiac rhythm management market as well as the diagnostic market. In the field of cardiac rhythm management, all...
Analysis of:
Schering-Plough Announces Initiation Of Two Phase III Clinical Trials For Novel Selective Antiplatelet Therapy (TRA-SCH 530348) (www.medicalnewstoday.com)
Three key points1) Large unmet need2) Need to assess efficacy against current available treatment3) Safety issues need to be clarified.
Analysis of:
Are Higher Doses Of Cholesterol Drugs Worth The Extra Money? Only Sometimes, Study Says (www.medcompare.com)
The Michigan study incorrectly perpetuates the myth that only death matters. Quality of life is exceedingly important to baby boomers- perhaps more so than life or death.
Analysis of:
Consumer Outreach Boosts Generic Cholesterol-Fighting Drugs (www.pharmalive.com)
This article summarizes the DTC strategies used to encourage generic utilization for prescription therapies, changing the dynamic from the perception that these therapies are inferior but acceptable alternatives to branded therapies to the impression that these are superior from a consumer value st...
Analysis of:
Abbott Submits New Drug Application For Combination Niaspan(R)/Simvastatin Tablet (www.medicalnewstoday.com)
1. Physicians are realizing the huge importance of Outcome based trials in CV risk reduction2. HATS in 2001 used Simvastatin + Niacin to achieve a 90% RRR in CV events3. AIM-HIGH is going on now using Simvastatin + Niaspan (Simcor) to confirm these findings4. Simcor should be...